居里 CRIS 深 滬
已收盤 08-07 16:00:00 美东时间
4.02
-0.390
-8.84%
華盛通- 最 高4.35
- 今 開4.35
- 成交量 7.00万股
- 最 低 3.955
- 昨 收 4.41
- 總市值 783.47万
- 52周最高 39.00
- 市盈率 靜 --
- 換手率 3.59%
- 52周最低 3.612
- 委 比 0.87%
- 總股本 194.89万
- 歷史最高 11300.00
- 量 比 1.10
- 振 幅 8.96%
- 歷史最低 3.612
- 每 手 1
- 風險率 9.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Curis Regains Nasdaq Compliance, Faces One-Year Monitoring
Curis ( ($CRIS) ) has shared an update. On July 24, 2026, Curis, Inc. received ...
07-31 05:20
Curis Doses First Five Patients in TakeAim CLL Study
LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule I...
07-30 20:00
美股大行评级 | 最高120美元！大小摩等7家大行集体上调英特尔目标价；汇丰首予SpaceX"持有"评级，目标价115美元
今日重点评级关注：HC Wainwright & Co.：维持居里"买入"评级，目标价从17美元升至43美元；花旗：维持Klaviyo"买入"评级，目标价从31美元升至34美元
07-27 14:02
新股前瞻|核药产业爆发前夜，蓝纳成能否成为千亿赛道先行者？
此番东诚药业推动蓝纳成分拆赴港上市，既助力了这家尚处于研发投入期的子公司拓宽融资渠道、加速管线推进，也为港股投资者提供了分享核药赛道发展红利的难得机遇。
07-25 13:55
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
On Wednesday, Curis Inc. (NASDAQ:CRIS) announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance. The biotechnology firm detailed key advances across its ongoing clinical programs evaluating the oral IRAK4 and FLT3 inhibito...
07-25 02:03
HC Wainwright & Co. Maintains Buy on Curis, Raises Price Target to $43
HC Wainwright & Co. analyst Sara Nik maintains Curis (NASDAQ:CRIS) with a Buy and raises the price target from $17 to $43.
07-24 18:14
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates
Curis Inc. (NASDAQ:CRIS) on Wednesday announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance. The biotechnology firm detailed key advances across its ongoing clinical programs evaluating the oral IRAK4 and FLT3 inhibitor...
07-23 01:04
Why Q32 Bio Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of Q32 Bio Inc (NASDAQ:QTTB) rose sharply in pre-market trading as the company said it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial on Monday. Q32 Bio shares jumped 29.6% to $14.53 in pre-market trading. Here are some other stocks moving in pre-mark...
07-13 16:39
Curis Announces It Has Consented The First Six Patients In The TakeAim CLL Study
On June 26, 2026, Curis announced that eleven clinical sites had opened for enrollment in the TakeAim CLL study. Today, Curis is announcing that it has consented the first six patients in that study – and reaffirmed its guidance for the dosing of five CLL patients by the end of July 2026, with initi...
07-06 21:33
